An ongoing phase 3 placebo-controlled double-blinded SEARCH (Sorafenib and Erlotinib, a Randomized Trial Protocol for the Treatment of Patients with HCC) trial is being conducted in patients with advanced HCC and CP Class A liver cirrhosis to determine if the OS seen with sorafenib in advanced HCC can be improved by the addition of erlotinib, resulting in combined inhibition of EGF, VEGF, and the RAS/RAF/MEK signaling pathways [80]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.